GLP-1 microdosing: what it actually means and what the evidence says

Microdosis de GLP-1: qué significa de verdad y qué dice la evidencia

Let's start with the good news, because it exists and almost nobody leads with it: a low dose of a GLP-1 is still a dose that does something. It isn't water. It isn't an expensive placebo. There is a large trial published in The Lancet that measured exactly this, and the result is more encouraging than you'd expect.

That matters because a lot of people come to this conversation afraid. Afraid of the nausea they've heard about. Afraid of starting something they won't be able to sustain. Afraid that if they never reach the top dose, it isn't even worth trying. That last fear is the one the evidence takes apart best.

The lowest dose in the trial was not a token dose

In 2018, a phase 2 trial randomly assigned 957 adults with obesity to semaglutide at five different doses, to liraglutide, or to placebo, for 52 weeks. Every group started low and escalated every four weeks. The smallest dose in the study was 0.05 mg per day.

That is a tiny fraction of what is used today as a weekly maintenance dose. And even so:

Look at the jump from placebo to the first step: nearly three times the weight loss, on the smallest dose studied. And from 0.1 mg per day upward, between 37% and 65% of participants lost 10% or more of their body weight. In the placebo group, 10% did.

One important clarification, because this is easy to get wrong: those doses were daily, not weekly. They are two different schedules and they do not convert into each other with simple arithmetic. Don't read that table as a dosing instruction. Read it as what it is — a clean demonstration that a GLP-1's effect does not switch on only once you reach the top. It starts earlier.

What "microdosing" means — and what it doesn't

"Microdosing" is not an official term. It appears in no FDA-approved label, it does not define a specific amount, and there is no clinical consensus on where it begins or ends. It is a word that caught on online.

In practice, people use it for three fairly different things:

• Staying on a low step of the normal schedule for longer than usual instead of continuing to climb. This is within what the label anticipates and can be a reasonable medical decision.
• Using a dose below the approved starting step. Here there are no phase 3 trials backing it with the current weekly schedule.
• Stretching a vial by injecting less than prescribed so it lasts longer. This is not a clinical strategy. It is cost-cutting with a real risk of dosing error, and we see it more often than we'd like.

Separating the three is worth the effort, because the first is ordinary medicine and the third is how people end up in the emergency room.

The dose-response curve is not a straight line

Go back to the table above and you'll see something that shows up across pharmacology: the first steps are the ones that pay off most.

Placebo to 0.05 mg is a 3.7-point difference. 0.05 to 0.1 adds 2.6 more points. 0.1 to 0.2 adds about 3. And 0.2 to 0.3 added nothing: the 0.3 mg group lost slightly less than the 0.2 mg group, which in a trial this size simply means the curve was already flattening out there.

This has a very concrete practical consequence. The useful question is not "what's the highest dose I can get to?" The useful question is "what's the lowest dose that gives me the result I need, with side effects I can live with?" That is a clinical question, and the answer is different for each person.

Your schedule already starts at a low dose

Most people don't realize this: if you start an injectable semaglutide program following the approved label, your first weeks are already a low dose by design. The schedule looks like this:

And there are two details in the approved document itself that almost nobody mentions:

First: "if patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks." In other words, staying longer on a step isn't breaking the protocol. It's written into the protocol.

Second: the label allows that if the 2.4 mg weekly maintenance dose isn't tolerated, the dose can be decreased to 1.7 mg weekly and stay there. A lower maintenance dose is a recognized option, not a consolation prize.

If you're in your first month, we cover it in more detail in your first month on a GLP-1.

What a lower dose can give you

Three real things, and none of them is a promise about your result.

Fewer digestive side effects. In the 2018 trial, the most common adverse events were gastrointestinal symptoms — mainly nausea — and they were dose-related. In the large tirzepatide trial, GI events were mostly mild to moderate and occurred primarily during dose escalation. Escalation is the uncomfortable stretch. Climbing it more slowly, or stopping earlier, changes that experience.

A better chance of still being on it in six months. This isn't a lab finding, it's clinical common sense: the treatment you can tolerate is the treatment you can keep. And as you'll see two sections down, keeping it is what actually moves the needle at one year.

An honest starting point if you're scared to start. If what's holding you back is the nausea stories, knowing that the first step already does something measurable changes the conversation. You don't have to sign up for the maximum dose to begin.

And what it can cost you

Here comes the part a salesperson would skip, and we won't.

Average weight loss on a low dose is smaller. In the 2018 trial, the lowest step gave −6.0% and the highest gave −13.8%. Those are two very different outcomes, and both are real. In the phase 3 trial of semaglutide 2.4 mg weekly, the mean change at 68 weeks was −14.9% versus −2.4% on placebo.

So: a low dose is not "the same thing but gentler." It is less average effect in exchange for fewer side effects. That trade may be the right one for you or it may not, and that depends on your starting point, your metabolic health and what you're trying to achieve. It is exactly the kind of decision you shouldn't make from reading an article — including ours.

The number that decides almost everything: continue or stop

If you take only one number away from this guide, make it this one.

A phase 3 trial took 803 adults who had already reached the maintenance dose after a 20-week run-in, with an average loss of 10.6%. It then randomized them: some continued treatment for another 48 weeks, others switched to placebo. Both groups kept the lifestyle support.

Fourteen and a half points of difference — not from changing dose, but from continuing versus stopping. That's the real hierarchy: consistency outweighs the step. A low dose you keep for two years beats a high dose you abandon in month three because you couldn't stand it.

We cover that side of it in how to prevent weight regain.

Tirzepatide: same logic, different scale

With tirzepatide the pattern repeats, at larger numbers. The phase 3 trial in 2,539 adults compared 5 mg, 10 mg and 15 mg weekly against placebo over 72 weeks:

Look at the shape of that curve again. The lowest dose in the study — 5 mg — already gave −15.0%, and 85% of that group lost 5% or more of their body weight. Tripling the dose to 15 mg added about 6 more points. A lot, yes. But not triple.

If you're choosing between the two molecules, we compare them in semaglutide vs. tirzepatide.

B12 and glycine: why they're in there

Several compounded formulations combine the GLP-1 with vitamin B12 or glycine, and the reasonable question is whether that adds anything.

Straight answer: there is no evidence that B12 or glycine add weight loss. The effect you're after comes from the GLP-1. B12 participates in energy metabolism and a deficiency causes real fatigue, so correcting low levels makes sense for someone who has them — but that's treating a deficiency, not accelerating a diet. Glycine is an amino acid that, in these formulations, mostly serves a formulation role.

If an ad suggests the vitamin in the vial is what's going to make the difference, be skeptical. That's not where the mechanism lives.

The real risk of microdosing on your own

This is where the conversation stops being theoretical.

The FDA issued a specific alert to health care providers, compounders and patients about dosing errors with compounded injectable semaglutide. The pattern repeats: multi-dose vials, syringes marked in units, instructions written in milligrams or milliliters, and people doing the conversion at the kitchen table. Cases have been reported of people administering several times the intended dose.

A badly measured low dose is not a low dose. It's a lottery. And the error doesn't only run downward.

So the answer isn't "use less," it's "let the person licensed to make that call make it and write it down." Once you start your program, a licensed physician reviews your case — habits, stress, sleep and medical history — and orders labs only if they consider it necessary. The dose, the step and how fast you climb are part of that conversation, not of an internet search.

So your expectations are the right ones

Three things, briefly, so you walk into this with your feet on the ground:

• Trial numbers are group averages. Within every group there were people well above and well below. Your result isn't in that table.
• The daily doses from the 2018 trial do not translate to a weekly schedule. They're useful for understanding the shape of the curve, not for calculating your injection.
• A lower dose is not a free shortcut. It's a trade: fewer side effects for less average effect. Choosing it well takes someone who knows your case.

What you can take as settled: starting low is a legitimate way to start, and continuing is what counts most.

Who is this NOT for?

• If you have a personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2.
• If you are pregnant, trying to become pregnant, or breastfeeding.
• If you have a history of pancreatitis or gastroparesis.
• If you have significant kidney or liver disease.
• If your plan is to inject less than prescribed to stretch the vial. That isn't microdosing, it's a dosing error waiting to happen.
• If you want a low dose so you don't have to change anything else. The medication doesn't replace protein, sleep or strength work.

Once you start your program, a licensed physician reviews your case and orders labs only if they consider it necessary. If your case suggests this isn't right for you, we'll tell you. Your trust is worth more than a sale.

GLP-1 programs with FDA-approved medications (Wegovy®, Foundayo™, Ozempic®) from $149/month, by telemedicine, in Spanish and English

Real clinical oversight, in English and Spanish, with ongoing follow-up. If your case calls for going slowly, we go slowly.

Eligibility is determined by medical evaluation. Individual results vary and are not guaranteed.

Frequently asked questions

Does GLP-1 microdosing work?

It depends what you mean by microdosing. In the 2018 phase 2 trial, the lowest dose studied — 0.05 mg per day — produced −6.0% weight loss at 52 weeks versus −2.3% on placebo. That's a real, measurable effect, and it's smaller than what the higher doses produced. Those doses were daily and don't translate to the current weekly schedule.

Is it the same as staying on a low step of the normal schedule?

No, and the difference matters. Staying longer on a step is anticipated in the FDA-approved label, which even suggests delaying escalation by four weeks if a dose isn't tolerated. Inventing a dose below the approved starting step is a different thing, with no phase 3 trials behind it.

Will I have less nausea on a lower dose?

Probably, but not guaranteed. In the trials, GI symptoms were dose-related and concentrated during escalation. Climbing more slowly usually makes that stretch more manageable. We cover it separately in managing GLP-1 side effects.

Can I stay on a low dose indefinitely?

That's a medical decision, and it's a recognized option: the approved label allows 1.7 mg weekly as maintenance if 2.4 mg isn't tolerated. What the evidence does make clear is that stopping treatment is associated with regaining weight.

Can I inject less to make the vial last longer?

Not on your own. The FDA issued an alert about dosing errors with compounded semaglutide, including cases where people received several times the intended dose while converting between units, milliliters and milligrams. If cost is the problem, raise it with your physician instead of improvising the measurement.

Does the B12 in the formulation help with weight loss?

There's no evidence it adds weight loss. Correcting a B12 deficiency can improve fatigue in someone whose levels are low, but the effect on weight comes from the GLP-1.

Do I need labs before starting?

Once you start your program, a licensed physician reviews your case — habits, stress, sleep and medical history — and orders labs only if they consider it necessary. It is not automatic and not required for everyone.

How long until I see results?

We can't give you a number or a timeline, and be skeptical of anyone who does. What is published is the trial design: the daily semaglutide trial measured at 52 weeks, the 2.4 mg weekly trial at 68, and the tirzepatide trial at 72. Individual results vary and are not guaranteed.

Do you offer care in Spanish?

Yes. All of our content and our care are available in Spanish and English.

Sources

• O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637-649. — DOI · via PubMed
• Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. — DOI · via PubMed
• Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. — DOI · via PubMed
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. — DOI · via PubMed
• U.S. Food and Drug Administration. WEGOVY (semaglutide) injection — Highlights of Prescribing Information. — accessdata.fda.gov
• U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. — fda.gov

Your trust is worth more than a sale.

More information →

This article is informational and is not medical advice. SCTS1 does not prescribe medications. All medical care, prescriptions and treatment plans are provided by licensed physicians through our partner platform, and compounded preparations are dispensed by licensed pharmacies. Eligibility is determined by a licensed provider through medical evaluation. The doses and escalation schedules mentioned come from approved prescribing information and published trials, and do not replace your physician's instructions; do not change your dose on your own. "Microdosing" is not a recognized term in approved prescribing information. Individual results vary and are not guaranteed.